Announcements Trials
Browse Landscape

Phase

Phase 2 2

Status

Active not recruiting 3Unknown 2Withdrawn 1

Sponsor Class

NIH 2

Study Type

Interventional 2

Sponsor

Cancer Type

Gynecologic 2

Conditions

Carcinoma, Ovarian Epithelial 3Ovarian Neoplasms 2Fallopian Tube Neoplasms 2

Interventions

Paclitaxel 16Carboplatin 15Bevacizumab 7Hyperthermic Intraperitoneal Chemotherapy 5Cisplatin 4Taxes 3Gemcitabine 3Cytoreduction Surgical Procedures 3Chemotherapy, Adjuvant 3oregovomab 2niraparib 2fluzoparib 2Topotecan 2ST 1481 2Neoadjuvant Therapy 2Methods 2Immunohistochemistry 2Ifosfamide 2Gene Expression Profiling 2Filgrastim 2Educational Status 2Early Intervention, Educational 2Amplified Fragment Length Polymorphism Analysis 2rucaparib 1pembrolizumab 1paclitaxel poliglumex 1olaparib 1navicixizumab 1mirvetuximab soravtansine 1liposomal doxorubicin 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Unknown × Fallopian Tube Neoplasms × oregovomab × Clear all
NCT00003634 2013-11-06

Monoclonal Antibody Therapy in Treating Patients With Residual Disease From Stage III or Stage IV Ovarian Epithelial, Fallopian Tube, or Peritoneal Cancer Following Surgery and Chemotherapy

National Cancer Institute (NCI)

Phase 2 Unknown
400 enrolled
Gynecologic

Carcinoma, Ovarian Epithelial, Fallopian Tube Neoplasms, Ovarian Neoplasms

NCT00004064 2013-11-06

Monoclonal Antibody Therapy in Treating Patients With Ovarian, Fallopian Tube, or Peritoneal Cancer

National Cancer Institute (NCI)

Phase 2 Unknown
102 enrolled
Gynecologic

Carcinoma, Ovarian Epithelial, Fallopian Tube Neoplasms, Ovarian Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡